ANDREW S. BOYER - 30 Jun 2021 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
Executive Vice President
Signature
/s/ Meredith Cook, Attorney-in-Fact
Issuer symbol
AMRX
Transactions as of
30 Jun 2021
Transactions value $
-$59,305
Form type
4
Filing time
01 Jul 2021, 16:03:44 UTC
Previous filing
11 May 2021
Next filing
01 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Options Exercise +23.1K +16.53% 163K 30 Jun 2021 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -$59.3K -11.6K -7.11% $5.12 151K 30 Jun 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Options Exercise $0 -23.1K -33.33% $0.00 46.2K 30 Jun 2021 Class A Common Stock 23.1K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4 On August 1, 2021, the reporting person was granted 69,284 restricted stock units vesting in three equal installments beginning on June 30, 2021.